Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Suyash Mohan

Showing results (141-150 of 160) with videos related to

Pageof 16
Sort By:
Journal of Neuro-Oncology|April 25, 2026
Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort studyCole Friedes, Melanie Berger, Lauren Linkowski, et al.
Scientific Reports|May 24, 2022
Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastomaAnahita Fathi Kazerooni, Sanjay Saxena, Erik Toorens, et al.
JCO Clinical Cancer Informatics|March 20, 2020
Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in GlioblastomaAnahita Fathi Kazerooni, Hamed Akbari, Gaurav Shukla, et al.
Cell|September 22, 2020
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T ImmunotherapiesKevin R Parker, Denis Migliorini, Eric Perkey, et al.
Science Translational Medicine|July 21, 2017
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastomaDonald M O'Rourke, MacLean P Nasrallah, Arati Desai, et al.
Communications Medicine|March 2, 2025
The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic driversAnahita Fathi Kazerooni, Hamed Akbari, Xiaoju Hu, et al.
The Oncologist|February 15, 2026
Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted TherapyIan Messing, Lauren Linkowski, Matthew D Riina, et al.
Journal of Medical Imaging (Bellingham, Wash.)|September 2, 2024
Predicting peritumoral glioblastoma infiltration and subsequent recurrence using deep-learning-based analysis of multi-parametric magnetic resonance imagingSunwoo Kwak, Hamed Akbari, Jose A Garcia, et al.
AJNR. American Journal of Neuroradiology|April 29, 2024
Sex-Specific Differences in Patients with <i>IDH1</i>-Wild-Type Grade 4 Glioma in the ReSPOND ConsortiumSree Gongala, Jose A Garcia, Nisha Korakavi, et al.
Nature Communications|May 13, 2026
Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot studyHamed Akbari, Suyash Mohan, Fang Liu, et al.
Pageof 16

Showing results (141-150 of 160) with videos related to

Sort By:
Pageof 16
Journal of Neuro-Oncology|April 25, 2026
Clinical, molecular, and immunologic determinants of survival in WHO-defined IDH-wildtype glioblastoma treated with radiotherapy: a large real-world cohort studyCole Friedes, Melanie Berger, Lauren Linkowski, et al.
Scientific Reports|May 24, 2022
Clinical measures, radiomics, and genomics offer synergistic value in AI-based prediction of overall survival in patients with glioblastomaAnahita Fathi Kazerooni, Sanjay Saxena, Erik Toorens, et al.
JCO Clinical Cancer Informatics|March 20, 2020
Cancer Imaging Phenomics via CaPTk: Multi-Institutional Prediction of Progression-Free Survival and Pattern of Recurrence in GlioblastomaAnahita Fathi Kazerooni, Hamed Akbari, Gaurav Shukla, et al.
Cell|September 22, 2020
Single-Cell Analyses Identify Brain Mural Cells Expressing CD19 as Potential Off-Tumor Targets for CAR-T ImmunotherapiesKevin R Parker, Denis Migliorini, Eric Perkey, et al.
Science Translational Medicine|July 21, 2017
A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastomaDonald M O'Rourke, MacLean P Nasrallah, Arati Desai, et al.
Communications Medicine|March 2, 2025
The radiogenomic and spatiogenomic landscapes of glioblastoma and their relationship to oncogenic driversAnahita Fathi Kazerooni, Hamed Akbari, Xiaoju Hu, et al.
The Oncologist|February 15, 2026
Outcomes after SRS and Ipilimumab plus Nivolumab for Melanoma Brain Metastases Following Prior Immune Checkpoint Inhibitor or Targeted TherapyIan Messing, Lauren Linkowski, Matthew D Riina, et al.
Journal of Medical Imaging (Bellingham, Wash.)|September 2, 2024
Predicting peritumoral glioblastoma infiltration and subsequent recurrence using deep-learning-based analysis of multi-parametric magnetic resonance imagingSunwoo Kwak, Hamed Akbari, Jose A Garcia, et al.
AJNR. American Journal of Neuroradiology|April 29, 2024
Sex-Specific Differences in Patients with <i>IDH1</i>-Wild-Type Grade 4 Glioma in the ReSPOND ConsortiumSree Gongala, Jose A Garcia, Nisha Korakavi, et al.
Nature Communications|May 13, 2026
Personalized machine learning-guided radiation dose escalation in newly diagnosed glioblastoma: prospective pilot studyHamed Akbari, Suyash Mohan, Fang Liu, et al.
Pageof 16